Overview

A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction

Status:
Terminated
Trial end date:
2019-04-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is test the safety and tolerability of BMS-986224 and its effects on the body in healthy subjects and subjects with chronic heart failure with reduced ejection fraction
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb